Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. IK-930 is a TEAD inhibitor designed to target the Hippo signaling pathway. Earlier this year, IK-930 was granted the FDA orphan drug designation for the treatment of patients having malignant […]
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that its lead candidate, ONCOS-102, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of malignant pleural mesothelioma, a rare and aggressive cancer. FDA’s Recognition Enhances Clinical Development The FDA’s […]
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) in adults. The approval is for Opdivo 360 mg every three weeks with 1 mg/kg every six weeks (injections for intravenous use) of […]